Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RGS4 | P49798 | 1/20 | 0.30 |
| ▸ | RGS8 | P57771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21261849 | 0.92 | BRD4 (0.39) | BRD4BRD2LMNAMAPTKMT2A | |
| SCHEMBL2754568 | 0.88 | LMNA (0.33) | BRD4BRD2LMNAMAPTPOLB | |
| SCHEMBL11930001 | 0.78 | POLB (0.31) | LMNAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL21037734 | 0.74 | BRD4 (0.33) | BRD4BRD2LMNAKMT2AMEN1 | |
| SCHEMBL12146257 | 0.72 | — | — | |
| SCHEMBL12386592 | 0.71 | BRD4 (0.32) | BRD4BRD2 | |
| SCHEMBL11930004 | 0.70 | CRBN (0.38) | — | |
| SCHEMBL23346774 | 0.70 | LMNA (0.31) | LMNAMAPT | |
| SCHEMBL21261850 | 0.70 | — | — | |
| SCHEMBL11930011 | 0.70 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-9150414-B2 | Nanocomposite and dispersion comprising the same | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | BRD4 2783/4885BRD2 3401/4885LMNA 1174/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | BRD4 1871/4885BRD2 3445/4885LMNA 4145/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | BRD4 2783/4885BRD2 3401/4885LMNA 1174/4885 |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | BRD4 684/4885BRD2 820/4885LMNA 3118/4885 |
| US-10561657-B2 | Pyrrolopyrimidine compound | JAK2, JAK1, JAK3 | BRD4 924/4885BRD2 1901/4885LMNA 4875/4885 |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | BRD4 679/4885BRD2 990/4885LMNA 3397/4885 |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | JAK2, JAK1, JAK3 | BRD4 924/4885BRD2 1901/4885LMNA 4875/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | BRD4 2783/4885BRD2 3401/4885LMNA 1174/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | BRD4 2783/4885BRD2 3401/4885LMNA 1174/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | BRD4 605/4885BRD2 611/4885LMNA 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.